Univercells Technologies, a provider of biomanufacturing technologies for viral production, has announced a strategic partnership with RoosterBio, a supplier of human mesenchymal stem/stromal cells (hMSCs), highly engineered media, and hMSC bioprocess systems. The partnership is aimed to optimise manufacturing of extracellular vesicles (EVs) using scalable and continuous bioprocessing technologies.
The companies say their goal is to deliver solutions for exosomes manufacture, leveraging Univercells’ intensified and integrated platforms and RoosterBio’s hMSC bioprocess and highly engineered media systems. As part of the partnership, RoosterBio will establish EV production process using their hMSCs from microcarriers in the scale-X hydro fixed-bed bioreactor which features 2.4 sqm surface for cell growth. Following initial optimisation to confirm cell growth, productivity, and product quality, the companies plan to develop a continuous process in perfusion mode.
Tim Kelly, CEO of RoosterBio said: “Together, Univercells Technologies and RoosterBio will leverage our novel technologies and expertise to accelerate our customers’ journey from preclinical development to commercialisation, reducing complexity and costs to make these life-saving therapies accessible for all patients.”
“Exosomes have emerged as a promising technology for advanced therapies such as viral vaccines and gene therapies. We are proud to partner with RoosterBio to demonstrate how purposefully designed technologies such as the scale-X bioreactor portfolio can enable the rapid delivery of reliable and affordable regenerative therapies,” said Mathias Garny, CEO of Univercells Technologies.
Both companies will look to extend this study among the scale-X carbo bioreactor (10 and 30 sqm growth surface) with integrated in-line product concentration enabling continuous exosomes manufacturing.
